Pharmacogenomics Market by Technology, Application - Global Industry Analysis & Forecast to 2027
Published On : June 2022 Pages : 150 Category: Pharma & Healthcare Report Code : HC063903
Pharmacogenomics Market by Technology (Microarray, Mass Spectrometry, Polymerase Chain Reaction, Sequencing, Electrophoresis and Other) Application (Infectious diseases, Neurological diseases, Pain management, Oncology, Cardiovascular diseases, Psychiatry, Others) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Pharmacogenomics Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Pharmacogenomics is a part of genetics which deals with the determination of the reaction of a person to specific medications. It is a blend of pharmacology – the art of medications and genomics which means the investigation of qualities and their functions. Pharmacogenomics strategies are utilized for the advancement of successful and safe drugs with specific genetic cosmetics.
Drivers and Restraints
Developing rates of chronic illnesses, for example, cancer, tuberculosis, HIV, and numerous others is a main consideration foreseen to drive the development of the worldwide pharmacogenomics market over the gauge years. Moreover, expanding number of geriatric populace, higher reception rate of pharmacogenomics technique by the different human services experts, and developing interest for customized treatment are a portion of different variables expected to drive income development of the objective market.
Regional Insights
Geographically, the market in Asia Pacific is anticipated to develop quickly trailed by North America.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Empire Genomics, LLC
- OneOme LLC
- Myriad Genetics Inc.
- Dynamic DNA Laboratories
- OPKO Health, Inc. (GeneDx)
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- Assurex Health Inc.
- Abbott Laboratories
- Hoffmann-La Roche AG
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Pharmacogenomics Market, By Technology, Estimates and Forecast, 2017-2027 ($Million)
o Microarray
o Electrophoresis
o Polymerase Chain Reaction
o Mass Spectrometry
o Sequencing
o Others
· Pharmacogenomics Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
o Infectious diseases
o Neurological diseases
o Oncology
o Pain management
o Cardiovascular diseases
o Psychiatry
o Others
· Pharmacogenomics Market, By Key Players
o Empire Genomics, LLC
o Illumina, Inc.
o Dynamic DNA Laboratories
o Hoffmann-La Roche AG
o Abbott Laboratories
o Assurex Health Inc.
o OPKO Health, Inc. (GeneDx)
o Myriad Genetics Inc.
o Thermo Fisher Scientific, Inc.
o OneOme LLC
· Pharmacogenomics Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Pharmacogenomics Market, By Country
o U.S. Pharmacogenomics Market
o Canada Pharmacogenomics Market
o Mexico Pharmacogenomics Market
o Europe
§ Europe Pharmacogenomics Market, By Country
o Germany Pharmacogenomics Market
o UK Pharmacogenomics Market
o France Pharmacogenomics Market
o Russia Pharmacogenomics Market
o Italy Pharmacogenomics Market
o Rest of Europe Pharmacogenomics Market
o Asia-Pacific
§ Asia-Pacific Pharmacogenomics Market, By Country
o China Pharmacogenomics Market
o Japan Pharmacogenomics Market
o South Korea Pharmacogenomics Market
o India Pharmacogenomics Market
o Southeast Asia Pharmacogenomics Market
o Rest of Asia-Pacific Pharmacogenomics Market
o South America
§ South America Pharmacogenomics Market
o Brazil Pharmacogenomics Market
o Argentina Pharmacogenomics Market
o Columbia Pharmacogenomics Market
o Rest of South America Pharmacogenomics Market
o Middle East and Africa
§ Middle East and Africa Pharmacogenomics Market
o Saudi Arabia Pharmacogenomics Market
o UAE Pharmacogenomics Market
o Egypt Pharmacogenomics Market
o Nigeria Pharmacogenomics Market
o South Africa Pharmacogenomics Market
o Rest of MEA Pharmacogenomics Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Pharmacogenomics Market, By Technology
5.1. Introduction
5.2. Global Pharmacogenomics Revenue and Market Share by Technology (2017-2027)
5.2.1. Global Pharmacogenomics Revenue and Revenue Share by Technology (2017-2027)
5.3. Microarray
5.3.1. Global Microarray Revenue and Growth Rate (2017-2027)
5.4. Electrophoresis
5.4.1. Global Electrophoresis Revenue and Growth Rate (2017-2027)
5.5. Polymerase Chain Reaction
5.5.1. Global Polymerase Chain Reaction Revenue and Growth Rate (2017-2027)
5.6. Mass Spectrometry
5.6.1. Global Mass Spectrometry Revenue and Growth Rate (2017-2027)
5.7. Sequencing
5.7.1. Global Sequencing Revenue and Growth Rate (2017-2027)
5.8. Others
5.8.1. Global Others Revenue and Growth Rate (2017-2027)
6. Pharmacogenomics Market, By Application
6.1. Introduction
6.2. Global Pharmacogenomics Revenue and Market Share by Application (2017-2027)
6.2.1. Global Pharmacogenomics Revenue and Revenue Share by Application (2017-2027)
6.3. Infectious diseases
6.3.1. Global Infectious diseases Revenue and Growth Rate (2017-2027)
6.4. Neurological diseases
6.4.1. Global Neurological diseases Revenue and Growth Rate (2017-2027)
6.5. Oncology
6.5.1. Global Oncology Revenue and Growth Rate (2017-2027)
6.6. Pain management
6.6.1. Global Pain management Revenue and Growth Rate (2017-2027)
6.7. Cardiovascular diseases
6.7.1. Global Cardiovascular diseases Revenue and Growth Rate (2017-2027)
6.8. Psychiatry
6.8.1. Global Psychiatry Revenue and Growth Rate (2017-2027)
6.9. Others
6.9.1. Global Others Revenue and Growth Rate (2017-2027)
7. Pharmacogenomics Market, By Region
7.1. Introduction
7.2. Global Pharmacogenomics Revenue and Market Share by Regions
7.2.1. Global Pharmacogenomics Revenue by Regions (2017-2027)
7.3. North America Pharmacogenomics by Countries
7.3.1. North America Pharmacogenomics Revenue and Growth Rate (2017-2027)
7.3.2. North America Pharmacogenomics Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Pharmacogenomics by Countries
7.4.1. Europe Pharmacogenomics Revenue and Growth Rate (2017-2027)
7.4.2. Europe Pharmacogenomics Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Pharmacogenomics by Countries
7.5.1. Asia-Pacific Pharmacogenomics Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Pharmacogenomics Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Pharmacogenomics by Countries
7.6.1. South America Pharmacogenomics Revenue and Growth Rate (2017-2027)
7.6.2. South America Pharmacogenomics Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Pharmacogenomics by Countries
7.7.1. Middle East and Africa Pharmacogenomics Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Pharmacogenomics Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Empire Genomics, LLC
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Illumina, Inc.
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Dynamic DNA Laboratories
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Hoffmann-La Roche AG
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Abbott Laboratories
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Assurex Health Inc.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. OPKO Health, Inc. (GeneDx)
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Myriad Genetics Inc.
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Thermo Fisher Scientific, Inc.
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. OneOme LLC
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Pharmacogenomics Market Forecast (2017-2027)
9.1. Global Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Pharmacogenomics Market Forecast by Regions (2017-2027)
9.2.1. North America Pharmacogenomics Market Forecast (2017-2027)
9.2.1.1. United States Pharmacogenomics Market Forecast (2017-2027)
9.2.1.2. Canada Pharmacogenomics Market Forecast (2017-2027)
9.2.1.3. Mexico Pharmacogenomics Market Forecast (2017-2027)
9.2.2. Europe Pharmacogenomics Market Forecast (2017-2027)
9.2.2.1. Germany Pharmacogenomics Market Forecast (2017-2027)
9.2.2.2. France Pharmacogenomics Market Forecast (2017-2027)
9.2.2.3. UK Pharmacogenomics Market Forecast (2017-2027)
9.2.2.4. Russia Pharmacogenomics Market Forecast (2017-2027)
9.2.2.5. Italy Pharmacogenomics Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Pharmacogenomics Market Forecast (2017-2027)
9.2.3. Asia-Pacific Pharmacogenomics Market Forecast (2017-2027)
9.2.3.1. China Pharmacogenomics Market Forecast (2017-2027)
9.2.3.2. Japan Pharmacogenomics Market Forecast (2017-2027)
9.2.3.3. Korea Pharmacogenomics Market Forecast (2017-2027)
9.2.3.4. India Pharmacogenomics Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Pharmacogenomics Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Pharmacogenomics Market Forecast (2017-2027)
9.2.4. South America Pharmacogenomics Market Forecast (2017-2027)
9.2.4.1. Brazil Pharmacogenomics Market Forecast (2017-2027)
9.2.4.2. Argentina Pharmacogenomics Market Forecast (2017-2027)
9.2.4.3. Columbia Pharmacogenomics Market Forecast (2017-2027)
9.2.4.4. Rest of South America Pharmacogenomics Market Forecast (2017-2027)
9.2.5. Middle East and Africa Pharmacogenomics Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Pharmacogenomics Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Pharmacogenomics Market Forecast (2017-2027)
9.2.5.3. Egypt Pharmacogenomics Market Forecast (2017-2027)
9.2.5.4. Nigeria Pharmacogenomics Market Forecast (2017-2027)
9.2.5.5. South Africa Pharmacogenomics Market Forecast (2017-2027)
9.2.5.6. Turkey Pharmacogenomics Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Pharmacogenomics Market Forecast (2017-2027)
9.3. Pharmacogenomics Market Forecast by Technology (2017-2027)
9.3.1. Pharmacogenomics Forecast by Technology (2017-2027)
9.3.2. Pharmacogenomics Market Share Forecast by Technology (2017-2027)
9.4. Pharmacogenomics Market Forecast by Application (2017-2027)
9.4.1. Pharmacogenomics Forecast by Application (2017-2027)
9.4.2. Pharmacogenomics Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Pharmacogenomics Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Pharmacogenomics Revenue and Revenue Share by Technology (2017-2018)
Figure Global Microarray Revenue and Growth Rate (2017-2018)
Figure Global Electrophoresis Revenue and Growth Rate (2017-2018)
Figure Global Polymerase Chain Reaction Revenue and Growth Rate (2017-2018)
Figure Global Mass Spectrometry Revenue and Growth Rate (2017-2018)
Figure Global Sequencing Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Pharmacogenomics Revenue and Revenue Share by Application (2017-2018)
Figure Global Infectious diseases Revenue and Growth Rate (2017-2018)
Figure Global Neurological diseases Revenue and Growth Rate (2017-2018)
Figure Global Oncology Revenue and Growth Rate (2017-2018)
Figure Global Pain management Revenue and Growth Rate (2017-2018)
Figure Global Cardiovascular diseases Revenue and Growth Rate (2017-2018)
Figure Global Psychiatry Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Pharmacogenomics Revenue by Regions (2017-2018)
Figure North America Pharmacogenomics Growth Rate (2017-2018)
Figure North America Pharmacogenomics Revenue and Growth Rate (2017-2018)
Figure North America Pharmacogenomics by Countries (2017-2018)
Figure North America Pharmacogenomics Revenue (Million USD) by Countries (2017-2018)
Figure United States Pharmacogenomics Growth Rate (2017-2018)
Figure United States Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Pharmacogenomics Growth Rate (2017-2018)
Figure Canada Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Pharmacogenomics Growth Rate (2017-2018)
Figure Mexico Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Pharmacogenomics Growth Rate (2017-2018)
Figure Europe Pharmacogenomics Revenue and Growth Rate (2017-2018)
Figure Europe Pharmacogenomics by Countries (2017-2018)
Figure Europe Pharmacogenomics Revenue (Million USD) by Countries (2017-2018)
Figure Germany Pharmacogenomics Growth Rate (2017-2018)
Figure Germany Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Pharmacogenomics Growth Rate (2017-2018)
Figure France Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Pharmacogenomics Growth Rate (2017-2018)
Figure UK Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Pharmacogenomics Growth Rate (2017-2018)
Figure Russia Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Pharmacogenomics Growth Rate (2017-2018)
Figure Italy Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Pharmacogenomics Growth Rate (2017-2018)
Figure Rest of Europe Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Pharmacogenomics Growth Rate (2017-2018)
Figure Asia-Pacific Pharmacogenomics Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Pharmacogenomics by Countries (2017-2018)
Figure Asia-Pacific Pharmacogenomics Revenue (Million USD) by Countries (2017-2018)
Figure China Pharmacogenomics Growth Rate (2017-2018)
Figure China Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Pharmacogenomics Growth Rate (2017-2018)
Figure Japan Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Pharmacogenomics Growth Rate (2017-2018)
Figure Korea Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Pharmacogenomics Growth Rate (2017-2018)
Figure India Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Pharmacogenomics Growth Rate (2017-2018)
Figure Southeast Asia Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Pharmacogenomics Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Pharmacogenomics Growth Rate (2017-2018)
Figure South America Pharmacogenomics Revenue and Growth Rate (2017-2018)
Figure South America Pharmacogenomics by Countries (2017-2018)
Figure South America Pharmacogenomics Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Pharmacogenomics Growth Rate (2017-2018)
Figure Brazil Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Pharmacogenomics Growth Rate (2017-2018)
Figure Argentina Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Pharmacogenomics Growth Rate (2017-2018)
Figure Columbia Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Pharmacogenomics Growth Rate (2017-2018)
Figure Rest of South America Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Pharmacogenomics Growth Rate (2017-2018)
Figure Middle East and Africa Pharmacogenomics Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Pharmacogenomics by Countries (2017-2018)
Figure Middle East and Africa Pharmacogenomics Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Pharmacogenomics Growth Rate (2017-2018)
Figure Saudi Arabia Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Pharmacogenomics Growth Rate (2017-2018)
Figure United Arab Emirates Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Pharmacogenomics Growth Rate (2017-2018)
Figure Egypt Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Pharmacogenomics Growth Rate (2017-2018)
Figure Nigeria Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Pharmacogenomics Growth Rate (2017-2018)
Figure South Africa Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Pharmacogenomics Growth Rate (2017-2018)
Figure Turkey Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Pharmacogenomics Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Pharmacogenomics Revenue (Millions USD) and Growth Rate (2017-2018)
Table Empire Genomics, LLC Pharmacogenomics Financial Overview
Table Illumina, Inc. Pharmacogenomics Financial Overview
Table Dynamic DNA Laboratories Pharmacogenomics Financial Overview
Table Hoffmann-La Roche AG Pharmacogenomics Financial Overview
Table Abbott Laboratories Pharmacogenomics Financial Overview
Table Assurex Health Inc. Pharmacogenomics Financial Overview
Table OPKO Health, Inc. (GeneDx) Pharmacogenomics Financial Overview
Table Myriad Genetics Inc. Pharmacogenomics Financial Overview
Table Thermo Fisher Scientific, Inc. Pharmacogenomics Financial Overview
Table OneOme LLC Pharmacogenomics Financial Overview
Figure Global Pharmacogenomics Revenue (Millions USD) and Growth Rate (2018-2025)
Table Pharmacogenomics Market Forecast by Regions (2018-2025)
Figure North America Pharmacogenomics Market Forecast (2018-2025)
Figure United States Pharmacogenomics Market Forecast (2018-2025)
Figure Canada Pharmacogenomics Market Forecast (2018-2025)
Figure Mexico Pharmacogenomics Market Forecast (2018-2025)
Figure Europe Pharmacogenomics Market Forecast (2018-2025)
Figure Germany Pharmacogenomics Market Forecast (2018-2025)
Figure France Pharmacogenomics Market Forecast (2018-2025)
Figure UK Pharmacogenomics Market Forecast (2018-2025)
Figure Russia Pharmacogenomics Market Forecast (2018-2025)
Figure Italy Pharmacogenomics Market Forecast (2018-2025)
Figure Rest of Europe Pharmacogenomics Market Forecast (2018-2025)
Figure Asia-Pacific Pharmacogenomics Market Forecast (2018-2025)
Figure China Pharmacogenomics Market Forecast (2018-2025)
Figure Japan Pharmacogenomics Market Forecast (2018-2025)
Figure Korea Pharmacogenomics Market Forecast (2018-2025)
Figure India Pharmacogenomics Market Forecast (2018-2025)
Figure Southeast Asia Pharmacogenomics Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Pharmacogenomics Market Forecast (2018-2025)
Figure South America Pharmacogenomics Market Forecast (2018-2025)
Figure Brazil Pharmacogenomics Market Forecast (2018-2025)
Figure Argentina Pharmacogenomics Market Forecast (2018-2025)
Figure Columbia Pharmacogenomics Market Forecast (2018-2025)
Figure Rest of South America Pharmacogenomics Market Forecast (2018-2025)
Figure Middle East and Africa Pharmacogenomics Market Forecast (2018-2025)
Figure Saudi Arabia Pharmacogenomics Market Forecast (2018-2025)
Figure United Arab Emirates Pharmacogenomics Market Forecast (2018-2025)
Figure Egypt Pharmacogenomics Market Forecast (2018-2025)
Figure Nigeria Pharmacogenomics Market Forecast (2018-2025)
Figure South Africa Pharmacogenomics Market Forecast (2018-2025)
Figure Turkey Pharmacogenomics Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Pharmacogenomics Market Forecast (2018-2025)
Figure Global Pharmacogenomics Forecast by Technology (2018-2025)
Figure Global Pharmacogenomics Market Share Forecast by Technology (2018-2025)
Figure Global Pharmacogenomics Forecast by Technology (2018-2025)
Figure Global Pharmacogenomics Forecast by Application (2018-2025)
Figure Global Pharmacogenomics Market Share Forecast by Application (2018-2025)
Figure Global Pharmacogenomics Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|